Tag Archives: baxter

May, 2017

  • 31 May

    Baxter and Mayo Collaborate to Transform Patient Care

    DEERFIELD, Ill. & JACKSONVILLE, Fla.–(BUSINESS WIRE)–Baxter International Inc. (NYSE:BAX), a global medical products company, and Mayo Clinic today announced a new research and development collaboration to advance innovation across a spectrum of therapeutic areas where there are high unmet patient needs. The collaboration agreement will bring together the clinical and …

June, 2015

May, 2015

March, 2015

  • 13 March

    Baxter’s Investigational Hemophilia Drug Succeeds in Phase 3 Study

    Today, Baxter International Inc. announced positive results from its late-stage trial evaluating its investigational treatment for patients with hemophilia A or B. The company said that its BAX 817, an investigational recombinant factor VIIa (rFVIIa), demonstrated positive safety and efficacy results in its Phase III clinical trial in patients with …

  • 9 March

    CTI BioPharma and Baxter’s Myelofibrosis Drug Meets Primary Endpoint in Late-Stage Trial

    Baxter International and CTI BioPharma Corp. announced that its experimental blood cancer drug met its primary endpoint in a late-stage study. The companies announced top-line results for the primary endpoint from PERSIST-1, a Phase III registration clinical trial evaluating pacritinib, an oral JAK2/FLT3 multikinase inhibitor, for the treatment of patients …

  • 4 March

    Baxter Acquires Autoimmune Biotech SuppreMol

    Baxter International Inc. announced that it has agreed to acquire German biopharmaceutical company SuppreMol, expanding its portfolio of drugs for autoimmune diseases. Baxter is paying $225 million before working capital and other adjustments for the privately-held company, gaining SuppreMol’s early-stage development portfolio of novel biologic immunoregulatory therapeutics for treatment of …